Table 2 Correlation between immunological markers and clinical features of pro-B-ALL
Clinical features | CD15 | CD34 | NG2 | ||||||
|---|---|---|---|---|---|---|---|---|---|
Neg (%) | Pos (%) | P | Neg (%) | Pos (%) | P | Neg (%) | Pos (%) | P | |
Gender | |||||||||
 Male | 35 (58) | 9 (56) | 0.881 | 14 (54) | 55 (58) | 0.712 | 27 (59) | 17 (57) | 0.861 |
 Female | 25 (42) | 7 (44) | 12 (46) | 40 (42) | 19 (41) | 13 (43) | |||
Age (years) | |||||||||
 < 1 | 6 (10) | 4 (25) | 0.227 | 2 (8) | 9 (9) | 0.812 | 2 (4) | 8 (27) | 0.012 |
 1–10 | 45 (75) | 11 (69) | 20 (77) | 67 (71) | 36 (78) | 20 (67) | |||
 ≥ 10 | 9 (15) | 1 (6) | 4 (15) | 19 (20) | 8 (17) | 2 (7) | |||
WBC | |||||||||
 < 50 × 109/L | 42 (70) | 12 (75) | 0.695 | 18 (69) | 66 (69) | 0.981 | 35 (76) | 19 (63) | 0.231 |
 ≥ 50 × 109/L | 18 (30) | 4 (25) | 8 (31) | 29 (31) | 11 (24) | 11 (37) | |||
Prednisone response | |||||||||
 Good | 54 (90) | 16 (100) | 0.188 | 24 (92) | 88 (93) | 0.956 | 41 (89) | 29 (97) | 0.234 |
 Poor | 6 (10) | 0 (0) | 2 (8) | 7 (7) | 5 (11) | 1 (3) | |||
MRD at day 33 | |||||||||
 < 0.01% | 9 (17) | 3 (19) | 0.042 | 11 (26) | 16 (21) | 0.001 | 7 (18) | 5 (17) | 0.881 |
 0.01–1% | 38 (72) | 7 (44) | 10 (24) | 43 (57) | 26 (67) | 19 (63) | |||
 ≥ 1% | 6 (11) | 6 (38) | 21 (50) | 16 (21) | 6 (15) | 6 (20) | |||
MRD at day 78 | |||||||||
 < 0.1% | 46 (94) | 10 (67) | 0.005 | 18 (95) | 61 (84) | 0.213 | 32 (89) | 24 (86) | 0.703 |
 ≥ 0.1% | 3 (6) | 5 (33) | 1 (5) | 12 (16) | 4 (11) | 4 (14) | |||